{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:37:38Z","timestamp":1762353458684,"version":"build-2065373602"},"reference-count":20,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"5","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,5]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n                  <jats:p>Enhancing surveillance for adverse events following immunization remains a key global immunization priority. Many low- and middle-income countries (LMICs) are implementing new vaccines without the comprehensive safety monitoring typically conducted in high-income countries. Since 2017, the Global Immunization Safety Team at the US Centers for Disease Control and Prevention, in collaboration with partners, has supported establishing sentinel surveillance systems during vaccine introductions for safety monitoring in LMICs. Through these experiences, many lessons have been learned regarding project initiation, funding opportunities, standardizing data collection, background rate challenges, site selection considerations, and partner coordination. If vaccine safety is prioritized, sentinel surveillance enhances routine monitoring and generates valuable safety data, strengthening the immunization and regulatory programs. As many countries introduce and manufacture vaccines not previously monitored in high-income countries, lessons from safety monitoring during earlier vaccine introductions must be applied. Sustaining the gains in immunization that were hard-earned over the past decades depends on it.<\/jats:p>","DOI":"10.4269\/ajtmh.25-0363","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:11:36Z","timestamp":1756998696000},"page":"945-949","source":"Crossref","is-referenced-by-count":0,"title":["Strengthening New Vaccine Introduction in Low- and Middle-Income Countries: Establishing Hospital-Based Sentinel Surveillance for Vaccine Safety Monitoring"],"prefix":"10.4269","volume":"113","author":[{"given":"Anna","family":"Shaum","sequence":"first","affiliation":[{"name":"Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Blau","sequence":"additional","affiliation":[{"name":"Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Longley","sequence":"additional","affiliation":[{"name":"Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Global Health Program, College of Public Health, National Taiwan University, Taipei City, Taiwan;"},{"name":"National Taiwan University Children\u2019s Hospital, Taipei City, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Gidudu","sequence":"additional","affiliation":[{"name":"Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"year":"2024","key":"b1","article-title":"Immunization Agenda 2030: A Global Strategy to Leave No One Behind."},{"key":"b2","series-title":"BMJ Glob Health","first-page":"e015445","article-title":"Malaria vaccine rollout begins in Africa: The need to strengthen regulatory and safety surveillance systems in Africa","volume":"9","author":"Duga","year":"2024"},{"key":"b3","series-title":"BMJ Glob Health","first-page":"e014544","article-title":"Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: Lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group","volume":"9","author":"Chandler","year":"2024"},{"key":"b4","series-title":"Wkly Epidemiol Rec","first-page":"429","article-title":"Smallpox and mpox (orthopoxviruses) vaccine position paper","volume":"34","year":"2024"},{"key":"b5","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1321","article-title":"Progress in immunization safety monitoring\u2014Worldwide, 2020\u20132022","volume":"72","author":"Blau","year":"2023"},{"key":"b6","series-title":"Vaccine","first-page":"1009","article-title":"Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana","volume":"38","author":"Gidudu","year":"2020"},{"key":"b7","series-title":"Clin Infect Dis","first-page":"e927","article-title":"Evaluation of vaccine safety after the first public sector introduction of typhoid conjugate vaccine-navi Mumbai, India, 2018","volume":"73","author":"Longley","year":"2021"},{"key":"b8","series-title":"Vaccine","first-page":"3573","article-title":"Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe","volume":"40","author":"Shaum","year":"2022"},{"key":"b9","series-title":"Vaccine","first-page":"126197","article-title":"Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019\u20132020\u2014Preliminary report","volume":"42","author":"Casey","year":"2024"},{"key":"b10","series-title":"Lancet Glob Health","first-page":"e1213","article-title":"Safety of nOPV2 administered during a supplementary immunisation activity in Uganda, 2022: Data triangulation from a prospective cohort event monitoring programme and vaccine safety surveillance reports","volume":"13","author":"Longley","year":"2025"},{"key":"b11","series-title":"Vaccine","first-page":"126079","article-title":"Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia","volume":"42","author":"Sintayehu","year":"2024"},{"key":"b12","series-title":"Vaccine","first-page":"1812","article-title":"Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data","volume":"42","author":"Kochhar","year":"2024"},{"year":"2020","series-title":"COVID-19 Vaccines: Safety Surveillance Manual. Monitoring and Responding to Adverse Events Following Immunization","key":"b13"},{"key":"b14","series-title":"Vaccine","first-page":"B46","article-title":"Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010","volume":"30 (Suppl 2)","author":"Ouandaogo","year":"2012"},{"key":"b15","series-title":"Int Health","first-page":"676","article-title":"System and facility readiness assessment for conducting active surveillance of adverse events following immunization in Addis Ababa, Ethiopia","volume":"15","author":"Zeleke","year":"2023"},{"key":"b16","series-title":"Vaccine X","first-page":"100160","article-title":"Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: The WHO Global Vaccine safety Multi-Country collaboration project","volume":"11","author":"Sharan","year":"2022"},{"key":"b17","series-title":"Drug Saf","first-page":"1085","article-title":"Smart safety surveillance (3S): Multi-country experience of implementing the 3S concepts and principles","volume":"44","author":"Iessa","year":"2021"},{"key":"b18","series-title":"Curr Drug Saf","first-page":"60","article-title":"Vaccine safety monitoring systems in developing countries: An example of the Vietnam model","volume":"10","author":"Ali","year":"2015"},{"key":"b19","series-title":"Hum Vaccin Immunother","first-page":"2020529","article-title":"Capacity building for vaccine manufacturing across developing countries: The way forward","volume":"18","author":"Kumraj","year":"2022"},{"year":"2024","key":"b20","article-title":"The Change in African Vaccine Manufacturing Landscape."}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/113\/5\/article-p945.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/113\/5\/article-p945.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/113\/5\/article-p945.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:25:55Z","timestamp":1762352755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/113\/5\/article-p945.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":20,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.25-0363","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}